Skip to main content

Profile hero

Marcel Kaufmann


Disputes, litigation and arbitration, Global investigations

Very active in regulatory and healthcare compliance work

Chambers Europe 2015

Profile details

About Marcel Kaufmann

Marcel advises a broad range of multinationals and German companies on key regulatory issues and disputes.

He has specific sector experience in the healthcare and transport business, including pharmaceuticals, medical devices, railways and automotive.

His practice covers high-end litigation before administrative, civil and constitutional courts for both companies and public authorities, including highly visible mandates before the Federal Constitutional Court and the European Court of Justice.

In regulated industries, Marcel offers complex regulatory and compliance advice in national and global matters, internal investigations, transactions in sectors like healthcare or transport and complex restructuring mandates.

He speaks German and English.

Recent work

  • Advising Novartis on the purchase of GSK’s oncology business and the sale of its OTC business to a joint venture with GSK.
  • Advising Advent International on the sale of the MEDIAN group, the largest private rehabilitation care provider in Germany.
  • Advising a Chinese strategic investor on the acquisition of a global market leader in blood plasma and plasma-based pharmaceutical products.
  • Advising Deutsche Bahn in large disputes against competitors and German Laender regarding infrastructure fees.
  • Advising a leading manufacturer of medical devices in the review of his distribution contracts and the compliance management system.


  • Teaches administrative law at the University of Goettingen, and received a professorship from the university.


  • Nomos-Verlag 1997 Europäische Integration und Demokratieprinzip

  • Verlag C. H. Beck, 2010 (mit Prof. Dr. Thomas Lübbig, Dr. Hans-Joachim Prieß, Prof. Dr. Hermann Pünder und Prof. Dr. Michael Fehling) VO (EG) 1370/2007 Verordnung über öffentliche Personenverkehrsdienste. Kommentar

  • Verlag C. H. Beck, Band 93, 2014 (mit Dr. Alexander Meier, Peter von Czettritz und Dr. Marc Gabriel) Pharmarecht

  • DVBl 2002 (mit Dr. Benedikt Wolfers) Private als Anstaltsträger

  • ZUR 2004 (mit Dr. Benedikt Wolfers) Grüne Gentechnik: Koexistenz und Haftung

  • PharmR 2011 Zentrale sozialrechtliche Weichenstellungen des AMNOG

  • MedR 2012 (mit Dr. Jana Grühn) Das Versorgungsstrukturgesetz jenseits der Reform des Vertragsarztrechts

  • PharmR 2014 (mit Dr. Katharina Ludwig) Strafbarkeit von Arzneimittelmusterabgaben? Strafbarkeitsrisiko von pharmazeutischen Unternehmern nach dem StGB-Entwurf „Bestechlichkeit und Bestechung im Gesundheitswesen” bei Musterabgaben an Ärzte

  • N&R 2014 (mit Prof. Dr. Thomas Lübbig) Zum Begriff des Marktes und des Marktsegments in § 14 Abs. 4 AEG

  • PharmR 2015 Die arzneimittelrechtliche Zulassung als Zentralbegriff des Pharmarechts – zur Auslegung der Ausnahmen in Art. 3 und 5 der Richtlinie 2001/83